Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics

Journal of Clinical Medicine

Volumn 4, Issue 5, 2015, Pages 858-873

  Mansouri, Yasaman ^a   Guttman Yassky, Emma ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis; Biomarker; Eczema; Extrinsic; Immune phenotype; Intrinsic; T cells; Translational revolution

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DUPILUMAB; ELAFIN; EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; EOTAXIN 3; FILAGGRIN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 31; INTERLEUKIN 4; INTERLEUKIN 5; KI 67 ANTIGEN; LORICRIN; MACROPHAGE DERIVED CHEMOKINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PERIPLAKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN S 100; T6 ANTIGEN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNINDEXED DRUG;

ATOPIC DERMATITIS; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL PROLIFERATION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DOWN REGULATION; EPIDERMIS HYPERPLASIA; ETHNICITY; FINGER DERMATOGLYPHICS; GENE MUTATION; GENETIC VARIABILITY; HUMAN; IMMUNE SYSTEM; REVIEW; SKIN DEFECT; T LYMPHOCYTE ACTIVATION; ; PROTEIN EXPRESSION; ULTRAVIOLET B RADIATION; UPREGULATION;

EID: 85017096166     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4050858     Document Type: Review

References (96)

1. Finlay, A.Y. Quality of life in atopic dermatitis. J. Am. Acad. Dermatol. 2001, 45, S64–S66.
2. Schmitt, J.; Langan, S.; Deckert, S.; Svensson, A.; von Kobyletzki, L.; Thomas, K.; Spuls, P.; Harmonising Outcome Measure for Atopic Dermatitis (HOME) Initiative. Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation. J. Allergy Clin. Immunol. 2013, 132, 1337–1347.
3. Odhiambo, J.A.; Williams, H.C.; Clayton, T.O.; Robertson, C.F.; Asher, M.I.; Group, I.P.T.S. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J. Allergy Clin. Immunol. 2009, 124, 1251–1258.
4. Bieber, T. Atopic dermatitis. Ann. Dermatol. 2010, 22, 125–137.
5. Guttman-Yassky, E.; Nograles, K.E.; Krueger, J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis—Part I: Clinical and pathologic concepts. J. Allergy Clin. Immunol. 2011, 127, 1110–1118.
6. Boguniewicz, M.; Leung, D.Y. Atopic dermatitis: A disease of altered skin barrier and immune dysregulation. Immunol. Rev. 2011, 242, 233–246.
7. Gittler, J.K.; Shemer, A.; Suárez-Fariñas, M.; Fuentes-Duculan, J.; Gulewicz, K.J.; Wang, C.Q.; Mitsui, H.; Cardinale, I.; de Guzman Strong, C.; Krueger, J.G.; et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J. Allergy Clin. Immunol. 2012, 130, 1344–1354.
8. Baker, B.S. The role of microorganisms in atopic dermatitis. Clin. Exp. Immunol. 2006, 144, 1–9.
9. Shaker, M. New insights into the allergic march. Curr. Opin. Pediatr. 2014, 26, 516–520.
10. Bieber, T. Atopic dermatitis 2.0: From the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012, 67, 1475–1482.
11. Beck, L.A.; Thaçi, D.; Hamilton, J.D.; Graham, N.M.; Bieber, T.; Rocklin, R.; Ming, J.E.; Ren, H.; Kao, R.; Simpson, E.; et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. New Engl. J. Med. 2014, 371, 130–139.
12. Bae, J.M.; Choi, Y.Y.; Park, C.O.; Chung, K.Y.; Lee, K.H. Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J. Allergy Clin. Immunol. 2013, 132, 110–117.
13. Elias, P.M.; Steinhoff, M. “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J. Investig. Dermatol. 2008, 128, 1067–1070.
14. Elias, P.M.; Schmuth, M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr. Opin. Allergy Clin. Immunol. 2009, 9, 437–446.
15. Leung, D.Y.; Guttman-Yassky, E. Deciphering the complexities of atopic dermatitis: Shifting paradigms in treatment approaches. J. Allergy Clin. Immunol. 2014, 134, 769–779.
16. Bieber, T.; Novak, N. Pathogenesis of atopic dermatitis: New developments. Curr. Allergy Asthma Rep. 2009, 9, 291–294.
17. Palmer, C.N.; Irvine, A.D.; Terron-Kwiatkowski, A.; Zhao, Y.; Liao, H.; Lee, S.P.; Goudie, D.R.; Sandilands, A.; Campbell, L.E.; Smith, F.J.; et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006, 38, 441–446.
18. Irvine, A.D.; McLean, W.H.; Leung, D.Y. Filaggrin mutations associated with skin and allergic diseases. New Engl. J. Med. 2011, 365, 1315–1327.
19. Brown, S.J.; McLean, W.H. One remarkable molecule: Filaggrin. J. Investig. Dermatol. 2012, 132, 751–762.
20. Winge, M.C.; Bilcha, K.D.; Liedén, A.; Shibeshi, D.; Sandilands, A.; Wahlgren, C.F.; McLean, W.H.; Nordenskjöld, M.; Bradley, M. Novel filaggrin mutation but no other loss-of-function variants found in Ethiopian patients with atopic dermatitis. Br. J. Dermatol. 2011, 165, 1074–1080.
21. Margolis, D.J.; Gupta, J.; Apter, A.J.; Hoffstad, O.; Papadopoulos, M.; Rebbeck, T.R.; Wubbenhorst, B.; Mitra, N. Exome sequencing of filaggrin and related genes in African-American children with atopic dermatitis. J. Investig. Dermatol. 2014, 134, 2272–2274.
22. Jensen, J.M.; Scherer, A.; Wanke, C.; Bräutigam, M.; Bongiovanni, S.; Letzkus, M.; Staedtler, F.; Kehren, J.; Zuehlsdorf, M.; Schwarz, T.; et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012, 67, 413–423.
23. Khattri, S.; Shemer, A.; Rozenblit, M.; Dhingra, N.; Czarnowicki, T.; Finney, R.; Gilleaudeau, P.; Sullivan-Whalen, M.; Zheng, X.; Xu, H.; et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J. Allergy Clin. Immunol. 2014, 133, 1626–1634.
24. Hamilton, J.D.; Suárez-Fariñas, M.; Dhingra, N.; Cardinale, I.; Li, X.; Kostic, A.; Ming, J.E.; Radin, A.R.; Krueger, J.G.; Graham, N.; et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J. Allergy Clin. Immunol. 2014, 134, 1293–1300.
25. Hosokawa, C.; Takeuchi, S.; Furue, M. Severity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride. J. Dermatol. 2009, 36, 185–190.
26. Furue, M.; Kitahara, Y.; Akama, H.; Hojo, S.; Hayashi, N.; Nakagawa, H.; JAPANESE E6005 Study Investigators. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: Results of a randomized, vehicle-controlled, multicenter clinical trial. J. Dermatol. 2014, 41, 577–585.
27. Oranje, A.P.; Glazenburg, E.J.; Wolkerstorfer, A.; de Waard-van der Spek, F.B. Practical isses on interpretation of scoring atopic dermatitis: The SCORAD index, objective SCORAD and the three-item severity score. Br. J. Dermatol. 2007, 157, 645–648.
28. Hanifin, J.M.; Thurston, M.; Omoto, M.; Cherill, R.; Tofte, S.J.; Graeber, M. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp. Dermatol. 2001, 10, 11–18.
29. Iyengar, S.R.; Hoyte, E.G.; Loza, A.; Bonaccorso, S.; Chiang, D.; Umetsu, D.T.; Nadeau, K.C. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: A randomized, placebo-controlled clinical trial. Int. Arch. Allergy Immunol. 2013, 162, 89–93.
30. Bissonnette, R.; Poulin, Y.; Zhou, Y.; Tan, J.; Hong, H.C.; Webster, J.; Ip, W.; Tang, L.; Lyle, M. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: Results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br. J. Dermatol. 2012, 166, 853–860.
31. Papp, K.A.; Menter, A.; Strober, B.; Langley, R.G.; Buonanno, M.; Wolk, R.; Gupta, P.; Krishnaswami, S.; Tan, H.; Harness, J.A. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. Br. J. Dermatol. 2012, 167, 668–677.
32. Papp, K.A.; Kaufmann, R.; Thaçi, D.; Hu, C.; Sutherland, D.; Rohane, P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: Results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J. Eur. Acad. Dermatol. Venereol. 2013, 27, e376–e383.
33. Kimball, A.B.; Bensimon, A.G.; Guerin, A.; Yu, A.P.; Wu, E.Q.; Okun, M.M.; Bao, Y.; Gupta, S.R.; Mulani, P.M. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am. J. Clin. Dermatol. 2011, 12, 51–62.
34. Noda, S.; Krueger, J.G.; Guttman-Yassky, E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J. Allergy Clin. Immunol. 2015, 135, 324–336.
35. Chiricozzi, A.; Krueger, J.G. IL-17 targeted therapies for psoriasis. Expert Opin. Investig. Drugs 2013, 22, 993–1005.
36. Johnson-Huang, L.M.; Lowes, M.A.; Krueger, J.G. Putting together the psoriasis puzzle: An update on developing targeted therapies. Dis. Models Mech. 2012, 5, 423–433.
37. Guttman-Yassky, E.; Dhingra, N.; Leung, D.Y. New era of biologic therapeutics in atopic dermatitis. Expert Opin. Biol. Ther. 2013, 13, 549–561.
38. Guttman-Yassky, E.; Krueger, J.G. Psoriasis: EvZolution of pathogenic concepts and new therapies through phases of translational research. Br. J. Dermatol. 2007, 157, 1103–1115.
39. Suárez-Fariñas, M.; Tintle, S.J.; Shemer, A.; Chiricozzi, A.; Nograles, K.; Cardinale, I.; Duan, S.; Bowcock, A.M.; Krueger, J.G.; Guttman-Yassky, E. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 2011, 127, 954–964.
40. Tintle, S.; Shemer, A.; Suárez-Fariñas, M.; Fujita, H.; Gilleaudeau, P.; Sullivan-Whalen, M.; Johnson-Huang, L.; Chiricozzi, A.; Cardinale, I.; Duan, S.; et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J. Allergy Clin. Immunol. 2011, 128, 583–593.
41. Hayashida, S.; Uchi, H.; Moroi, Y.; Furue, M. Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis. J. Dermatol. Sci. 2011, 61, 180–186.
42. Jahnz-Rozyk, K.; Targowski, T.; Paluchowska, E.; Owczarek, W.; Kucharczyk, A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005, 60, 685–688.
43. Raap, U.; Wichmann, K.; Bruder, M.; Ständer, S.; Wedi, B.; Kapp, A.; Werferl, T. Correlation of IL-31 serum levels with severity of atopic dermatitis. J. Allergy Clin. Immunol. 2008, 122, 421–423.
44. Raap, U.; Weißmantel, S.; Gehring, M.; Eisenberg, A.M.; Kapp, A.; Fölster-Holst, R. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatr. Allergy Immunol. 2012, 23, 285–288.
45. Otsuka, A.; Tanioka, M.; Nakagawa, Y.; Honda, T.; Ikoma, A.; Miyachi, Y.; Kabashima, K. Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis. Eur. J. Dermatol. 2011, 21, 816–817.
46. Haeck, I.M.; Knol, M.J.; Ten Berge, O.; de Bruin-Weller, M.S.; Bruijnzeel-Koomen, C.A.; van Velsen, S.G. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial. J. Am. Acad. Dermatol. 2011, 64, 1074–1084.
47. Waxweiler, W.T.; Agans, R.; Morrell, D.S. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr. Dermatol. 2011, 28, 689–694.
48. Garmhausen, D.; Hagemann, T.; Bieber, T.; Dimitriou, I.; Fimmers, R.; Diepgen, T.; Novak, N. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013, 68, 498–506.
49. Suárez-Fariñas, M.; Gittler, J.K.; Shemer, A.; Cardinale, I.; Krueger, J.G.; Guttman-Yassky, E. Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. J. Allergy Clin. Immunol. 2013, 131, 577–579.
50. Rozenblit, M.; Suarez-Farinas, M.; Shemer, A.; Khattri, S.; Gilleaudeau, P.; Sullivan-Whalen, M.; Zheng, X.; Xu, H.; Cardinale, I.; Krueger, J.G.; et al. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. J. Allergy Clin. Immunol. 2014, 134, 955–957.
51. Suárez-Fariñas, M.; Dhingra, N.; Gittler, J.; Shemer, A.; Cardinale, I.; de Guzman Strong, C.; Krueger, J.G.; Guttman-Yassky, E. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J. Allergy Clin. Immunol. 2013, 132, 361–370.
52. Czarnowicki, T.; Krueger, J.G.; Guttman-Yassky, E. Skin barrier and immune dysregulation in atopic dermatitis: An evolving story with important clinical implications. J. Allergy Clin. Immunol. Pract. 2014, 2, 371–379.
53. Leung, D.Y. New insights into atopic dermatitis: Role of skin barrier and immune dysregulation. Allergol. Int. 2013, 62, 151–161.
54. Hamid, Q.; Boguniewicz, M.; Leung, D.Y. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J. Clin. Invest. 1994, 94, 870–876.
55. Park, H.Y.; Kim, C.R.; Huh, I.S.; Jung, M.Y.; Seo, E.Y.; Park, J.H.; Lee, D.Y.; Yang, J.M. Staphylococcus aureus colonization in acute and chronic skin lesions of patients with atopic dermatitis. Ann. Dermatol. 2013, 25, 410–416.
56. Akdis, C.A.; Akdis, M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. Clin. Exp. Allergy 2003, 33, 1618–1621.
57. Schmid-Grendelmeier, P.; Simon, D.; Simon, H.U.; Akdis, C.A.; Wüthrich, B. Epidemiology, clinical features, and immunology of the “intrinsic” (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001, 56, 841–849.
58. Simon, H.U.; Blaser, K. Inhibition of programmed eosinophil death: A key pathogenic event for eosinophilia? Immunol. Today 1995, 16, 53–55.
59. Wedi, B.; Raap, U.; Lewrick, H.; Kapp, A. Delayed eosinophil programmed cell death in vitro: A common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis. J. Allergy Clin. Immunol. 1997, 100, 536–543.
60. Jeong, C.W.; Ahn, K.S.; Rho, N.K.; Park, Y.D.; Lee, D.Y.; Lee, J.H.; Lee, E.S.; Yang, J.M. Differential in vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR. Clin. Exp. Allergy 2003, 33, 1717–1724.
61. Kabashima-Kubo, R.; Nakamura, M.; Sakabe, J.; Sugita, K.; Hino, R.; Mori, T.; Tobayashi, M.; Bito, T.; Kabashima, K.; Ogasawara, K.; et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: Possible immunological state of the intrinsic type. J. Dermatol. Sci. 2012, 67, 37–43.
62. Tokura, Y. Extrinsic and intrinsic types of atopic dermatitis. J. Dermatol. Sci. 2010, 58, 1–7.
63. Park, J.H.; Choi, Y.L.; Namkung, J.H.; Kim, W.S.; Lee, J.H.; Park, H.J.; et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: Correlations with laboratory variables. Br. J. Dermatol. 2006, 155, 778–783.
64. Hamid, Q.; Naseer, T.; Minshall, E.M.; Song, Y.L.; Boguniewicz, M.; Leung, D.Y. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J. Allergy Clin. Immunol. 1996, 98, 225–231.
65. Nograles, K.E.; Zaba, L.C.; Shemer, A.; Fuentes-Duculan, J.; Cardinale, I.; Kikuchi, T.; Ramon, M.; Bergman, R.; Krueger, J.G.; Guttman-Yassky, E. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J. Allergy Clin. Immunol. 2009, 123, 1244–1252.
66. Grewe, M.; Walther, S.; Gyufko, K.; Czech, W.; Schöpf, E.; Krutmann, J. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J. Investig. Dermatol. 1995, 105, 407–410.
67. Kato, A.; Fujii, E.; Watanabe, T.; Takashima, Y.; Matsushita, H.; Furuhashi, T.; Morita, A. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J. Dermatol. Sci. 2014, 74, 229–235.
68. Nograles, K.E.; Zaba, L.C.; Guttman-Yassky, E.; Fuentes-Duculan, J.; Suárez-Fariñas, M.; Cardinale, I.; Khatcherian, A.; Gonzalez, J.; Pierson, K.C.; White, T.R.; et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 2008, 159, 1092–1102.
69. Liang, S.C.; Tan, X.Y.; Luxenberg, D.P.; Karim, R.; Dunussi-Joannopoulos, K.; Collins, M.; Fouser, L.A. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 2006, 203, 2271–2279.
70. Novak, N.; Bieber, T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol. 2003, 112, 252–262.
71. Brenninkmeijer, E.E.; Spuls, P.I.; Legierse, C.M.; Lindeboom, R.; Smitt, J.H.; Bos, J.D. Clinical differences between atopic and atopiform dermatitis. J. Am. Acad. Dermatol. 2008, 58, 407–414.
72. Novak, N.; Kruse, S.; Kraft, S.; Geiger, E.; Klüken, H.; Fimmers, R.; Deichmann, K.A.; Bieber, T. Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4/interleukin-13 receptor gene: The dichotomy of extrinsic and intrinsic atopic dermatitis. J. Investig. Dermatol. 2002, 119, 870–875.
73. Shaw, T.E.; Currie, G.P.; Koudelka, C.W.; Simpson, E.L. Eczema prevalence in the United States: Data from the 2003 National Survey of Children’s Health. J. Investig. Dermatol. 2011, 131, 67–73.
74. Williams, H.C.; Pembroke, A.C.; Forsdyke, H.; Boodoo, G.; Hay, R.J.; Burney, P.G. London-born black Caribbean children are at increased risk of atopic dermatitis. J. Am. Acad. Dermatol. 1995, 32, 212–217.
75. Vachiramon, V.; Tey, H.L.; Thompson, A.E.; Yosipovitch, G. Atopic dermatitis in African American children: Addressing unmet needs of a common disease. Pediatr. Dermatol. 2012, 29, 395–402.
76. McLeod, H.L.; Lin, J.S.; Scott, E.P.; Pui, C.H.; Evans, W.E. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin. Pharmacol. Ther. 1994, 55, 15–20.
77. Dirks, N.L.; Huth, B.; Yates, C.R.; Meibohm, B. Pharmacokinetics of immunosuppressants: A perspective on ethnic differences. Int. J. Clin. Pharmacol. Ther. 2004, 42, 701–718.
78. Jungersted, J.M.; Høgh, J.K.; Hellgren, L.I.; Jemec, G.B.; Agner, T. Ethnicity and stratum corneum ceramides. Br. J. Dermatol. 2010, 163, 1169–1173.
79. Kompaore, F.; Marty, J.P.; Dupont, C. In vivo evaluation of the stratum corneum barrier function in blacks, Caucasians and Asians with two noninvasive methods. Skin Pharmacol. 1993, 6, 200–207.
80. Wilson, D.; Berardesca, E.; Maibach, H.I. In vitro transepidermal water loss: Differences between black and white human skin. Br. J. Dermatol. 1988, 119, 647–652.
81. Silverberg, J.I.; Hanifin, J.M. Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population-based study. J. Allergy Clin. Immunol. 2013, 132, 1132–1138.
82. Janumpally, S.R.; Feldman, S.R.; Gupta, A.K.; Fleischer, A.B. In the United States, blacks and Asian/Pacific Islanders are more likely than whites to seek medical care for atopic dermatitis. Arch. Dermatol. 2002, 138, 634–637.
83. Silverberg, J.I.; Becker, L.; Kwasny, M.; Menter, A.; Cordoro, K.M.; Paller, A.S. Central obesity and high blood pressure in pediatric patients with atopic dermatitis. JAMA Dermatol. 2015, 151, 144–152.
84. Herd, R.M.; Tidman, M.J.; Prescott, R.J.; Hunter, J.A. The cost of atopic eczema. Br. J. Dermatol. 1996, 135, 20–23.
85. Herd, R.M. The financial impact on families of children with atopic dermatitis. Arch. Dermatol. 2002, 138, 819–820.
86. Jenner, N.; Campbell, J.; Marks, R. Morbidity and cost of atopic eczema in Australia. Australas. J. Dermatol. 2004, 45, 16–22.
87. Guttman-Yassky, E.; Nograles, K.E.; Krueger, J.G. Contrasting pathogenesis of atopic dermatitis and psoriasis—Part II: Immune cell subsets and therapeutic concepts. J. Allergy Clin. Immunol. 2011, 127, 1420–1432.
88. Novak, N.; Simon, D. Atopic dermatitis—From new pathophysiologic insights to individualized therapy. Allergy 2011, 66, 830–839.
89. Taylor, R.S.; Cooper, K.D.; Headington, J.T.; Ho, V.C.; Ellis, C.N.; Voorhees, J.J. Cyclosporine therapy for severe atopic dermatitis. J. Am. Acad. Dermatol. 1989, 21, 580–583.
90. Sowden, J.M.; Berth-Jones, J.; Ross, J.S.; Motley, R.J.; Marks, R.; Finlay, A.Y.; Salek, M.S.; Graham-Brown, R.A.; Allen, B.R.; Camp, R.D. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991, 338, 137–140.
91. Harper, J.I.; Ahmed, I.; Barclay, G.; Lacour, M.; Hoeger, P.; Cork, M.J.; Finlay, A.Y.; Wilson, N.J.; Graham-Brown, R.A.; Sowden, J.M.; et al. Cyclosporin for severe childhood atopic dermatitis: Short course versus continuous therapy. Br. J. Dermatol. 2000, 142, 52–58.
92. Schmitt, J.; Schmitt, N.; Meurer, M. Cyclosporin in the treatment of patients with atopic eczema—A systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. 2007, 21, 606–619.
93. Bieber, T.; Straeter, B. Off-label prescriptions for atopic dermatitis in Europe. Allergy 2015, 70, 6–11.
94. Patel, A.N.; Langan, S.M.; Batchelor, J.M. A randomized trial of methotrexate vs. azathioprine for severe atopic eczema: A critical appraisal. Br. J. Dermatol. 2012, 166, 701–704.
95. Roekevisch, E.; Spuls, P.I.; Kuester, D.; Limpens, J.; Schmitt, J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. J. Allergy Clin. Immunol. 2014, 133, 429–438.
96. Malajian, D.; Guttman-Yassky, E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine 2014, doi:10.1016/j.cyto.2014.11.023.